TY - JOUR
T1 - Secondary Hormonal Manipulations in Prostate Cancer
AU - Ryan, Charles J.
PY - 2006/8/1
Y1 - 2006/8/1
N2 - Targeting AIPC with therapies that affect the mechanisms of androgen receptor signaling despite a castrate testosterone milieu is an active and growing area of clinical research. At present, for patients with AIPC, the data support the maintenance of the castrate state, recognition of the AAWD phenomenon, the sequential use of oral antiandrogens, and a trial of estrogens or adrenal androgen-targeted therapies. Novel agents are being developed that seek to prolong the duration of clinical responses and the overall response rate.
AB - Targeting AIPC with therapies that affect the mechanisms of androgen receptor signaling despite a castrate testosterone milieu is an active and growing area of clinical research. At present, for patients with AIPC, the data support the maintenance of the castrate state, recognition of the AAWD phenomenon, the sequential use of oral antiandrogens, and a trial of estrogens or adrenal androgen-targeted therapies. Novel agents are being developed that seek to prolong the duration of clinical responses and the overall response rate.
UR - http://www.scopus.com/inward/record.url?scp=33746210089&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746210089&partnerID=8YFLogxK
U2 - 10.1016/j.hoc.2006.03.005
DO - 10.1016/j.hoc.2006.03.005
M3 - Review article
C2 - 16861123
AN - SCOPUS:33746210089
SN - 0889-8588
VL - 20
SP - 925
EP - 934
JO - Hematology/Oncology Clinics of North America
JF - Hematology/Oncology Clinics of North America
IS - 4
ER -
